Biotransformation of Trastuzumab and Pertuzumab in Breast Cancer Patients assessed by Affinity Enrichment and Ion Exchange Chromatography

Oladapo Olaleye, Baubek Spanov, Peter Buls, Anna van der Voort, Natalia Govorukhina, Gabe S. Sonke, Peter Horvatovich Nico C. van de Merbel, Rainer Bischoff

Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, A Deusinglaan 1, 9713 AV Groningen, The Netherlands

Drug Metabolism and Disposition

Manuscript Number - DMD-AR-2022-001094R1
Supporting Information

Figure S1: Overlaid LC-UV traces of trastuzumab (plots A, B and C) and pertuzumab (plots D, E and F) extracted from the plasma of 8 patients at different time points. LC-UV traces are shown in original form (A and D), after interpolation (B and E) and after interpolation with time alignment (C and F). The original and interpolated traces are shown between 0-100 minutes, while the interpolated and aligned traces are shown between 10-60 minutes, as this was the range from which the similarity score was calculated. S1-S8 refers to Subjects 1 to 8.
Figure S2: Hierarchical clustering of the heatmaps of Trastuzumab (A) and Pertuzumab (B) LC-UV traces between 8 patients. Similarity score has a range between 0 (completely different LC-UV traces) and 1 (identical LC-UV traces). The order of LC-UV traces in rows and columns was arranged after. S1-S8 refers to Subjects 1 to 8.